Rulicent 5 mg is a prescription oral tablet containing Ruxolitinib, a selective JAK1/JAK2 inhibitor. Manufactured by Incepta Pharmaceuticals, it is indicated for dermatological conditions like vitiligo and atopic dermatitis (eczema), as well as hematological disorders such as myelofibrosis and polycythemia vera.
Ruxolitinib inhibits the Janus Kinase (JAK) pathway, which is responsible for excessive inflammation and abnormal cell proliferation. By blocking this pathway, Rulicent 5 mg reduces inflammation, helps restore skin pigmentation, and regulates abnormal blood cell production.
🔹 Indications
-
Vitiligo: Non-segmental vitiligo for repigmentation
-
Atopic Dermatitis (Eczema): Chronic skin inflammation
-
Myelofibrosis: Reduces spleen size and disease-related symptoms
-
Polycythemia Vera: Controls excessive red blood cell production
🔹 Dosage and Administration
-
Take orally, as prescribed by the physician
-
Vitiligo/Eczema: Usually dermatologist-prescribed dosage
-
Blood disorders: Usually 5–10 mg twice daily depending on condition
Note: Avoid skipping doses; always follow medical advice.
🔹 Precautions
-
Monitor blood counts and liver function regularly
-
Avoid alcohol during treatment
-
Pregnant or breastfeeding women should consult a doctor
-
Report fever or infections immediately
🔹 Side Effects
-
Mild headache or dizziness
-
Rash or itching
-
Low blood counts (rare)
-
Increased infection risk (rare)
🔹 Storage
-
Store below 25°C, away from moisture and sunlight
-
Keep out of reach of children
